In this context, elucidating the mechanisms of CTLA-4 and PD-1 T-cell inhibitory signalling has led to development of promising cancer immunotherapy tools, including blocking monoclonal antibodies (mAb) targeting these so-called ‘immune checkpoints'4,5. The gene discussed is CTLA4; the disease is cancer.